Outcome of Board Meeting including Unaudited Financial Results for the quarter and nine months ended December 31, 2025 as approved by the Board
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Relic Technologies' Board approved unaudited financial results for Q3 FY26 and nine months ended December 31, 2025. On a standalone basis, the company reported no revenue from operations as its planned shift to pharma and wellness products is still awaiting regulatory approvals; standalone net profit stood at Rs. 17.38 lakhs for the quarter and Rs. 44.71 lakhs for 9M FY26, a swing from the prior year's loss of Rs. 147.49 lakhs. On a consolidated basis (including Relic Pharma Ltd and the recently acquired Truhealthy Wellness Pvt Ltd), revenue from operations grew about 46% year-on-year to Rs. 220.07 lakhs for 9M FY26, but the company posted a net loss of Rs. 400.79 lakhs for 9M, hit by Rs. 232.12 lakhs of exceptional items and a sharp jump in employee benefit expenses (from Rs. 22.73 lakhs to Rs. 333.38 lakhs). Statutory auditor D. Kothary & Co. issued an unmodified review opinion on both sets of results. Additionally, 4,41,164 warrants were converted into equity shares, raising paid-up capital from Rs. 360 lakhs to Rs. 559.12 lakhs.
Mixed picture for shareholders: standalone turned profitable but the consolidated business is loss-making as subsidiary operations ramp up, with significantly higher employee and operating costs pressuring margins. The warrant-driven equity infusion is constructive for the balance sheet, but near-term consolidated profitability remains a concern pending revenue scale-up from the pharma and wellness subsidiaries.